EI
SLNO

EAM Investors’s Soleno Therapeutics SLNO Stock Holding History

EAM Investors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,741
Closed -$3.58M – 330
2025
Q2 		$3.58M Sell
42,741
-6,807
-14% -$509K 0.54% 90
2025
Q1 		$3.54M Buy
+49,548
New +$2.41M 0.61% 66
2024
Q2 		– Sell
-64,411
Closed -$2.76M – 336
2024
Q1 		$2.76M Sell
64,411
-29,014
-31% -$1.31M 0.43% 129
2023
Q4 		$3.76M Sell
93,425
-45,905
-33% -$1.31M 0.67% 51
2023
Q3 		$4.11M Buy
+139,330
New +$843K 0.79% 8

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors's SLNO Position: Q3 2025 in Review

EAM Investors sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 42,741 shares — an estimated $3.58M sold.

EAM Investors first reported a position in SLNO in Q3 2023 and held it in 5 quarters. The position peaked at $4.11M in Q3 2023. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • EAM Investors reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EAM Investors sold 42,741 Soleno Therapeutics shares in Q3 2025, an estimated $3.58M.
  • EAM Investors first reported a position in Soleno Therapeutics in Q3 2023 and held it in 5 quarters.
  • EAM Investors's Soleno Therapeutics position peaked at $4.11M in Q3 2023.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.